CORDIS

EU research results

CORDIS

ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer

Fact Sheet

Reporting

Results

Objective

This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives. ERIA was instigated to coordinate research into ALK-related malignancies to facilitate the development of less-toxic and more efficacious therapies. ALK is increasingly recognised as a prevalent oncogene in a number of human malignancies and therefore poses a prominent clinical problem, which requires coordinated research into its oncogenic mechanisms. ERIA now conducts a collaborative multidisciplinary research programme at the interface of biomedical and bio-mechanistic approaches, which will be an excellent environment to train the next generation of European scientists. The 15 recruited fellows will be incorporated into international academic study groups (all partners of the ERIA network) to perform high calibre research and also will be exposed to environments from other sectors to broaden their experience. Secondments will include technical training within individual laboratories and SMEs (TissueGnostics, Galkem, Cambridge Life Sciences, Sofigen and Varionostics) as well as large Pharma (Roche). Training through research will be complemented with a balanced programme of transferable skills and access to local courses. The training of each fellow will be guided by a personal career development plan and supervised by a PhD committee panel. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into an international network. Thereby providing competence in state-of-the-art research and development at the forefront of translational science.

Programme(s)

H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers

Topic(s)

MSCA-ITN-2015-ETN - Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN)

Call for proposal

H2020-MSCA-ITN-2015

See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Address

Trinity Lane The Old Schools
Cb2 1tn Cambridge

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 546 575,76

Website

Contact the organisation

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 574 216,55

LUDWIG BOLTZMANN GESELLSCHAFT GMBH

Austria

EU Contribution

€ 193 585,69

Masarykova univerzita

Czechia

EU Contribution

€ 232 422,48

EBERHARD KARLS UNIVERSITAET TUEBINGEN

Germany

EU Contribution

€ 249 216,48

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA

Italy

EU Contribution

€ 258 061,32

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 525 751,20

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 249 216,48

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 258 061,32

JUSTUS-LIEBIG-UNIVERSITAET GIESSEN

Germany

EU Contribution

€ 249 216,48

INSTITUT GUSTAVE ROUSSY

France

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 263 659,32

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 249 216,48

Partners (10)

Sort alphabetically

Expand all

The Naked Scientists

TISSUEGNOSTICS GMBH

Roche Austria

GALKEM SRL

BIOLUTION GMBH

VARIONOSTIC GMBH

Central European Society of Anti-Cancer Research (CESAR)

MEDIZINISCHE UNIVERSITAT GRAZ

Cambridge Life sciences

Sofigen

Project information

ALKATRAS

Grant agreement ID: 675712

Project website

Status

Ongoing project

Start date

1 September 2015
End date

31 August 2019

Funded under:

H2020-EU.1.3.1.

Overall budget:

€ 3 849 199,56
EU contribution

€ 3 849 199,56

Coordinated by:

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

Periodic Reporting for period 1 - ALKATRAS (ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer)

Reporting period: 2015-09-01 to 2017-08-31

Summary of the context and overall objectives of the project

The objectives of ERIA (The European Research Initiative for ALK-Related Malignancies) as a network of scientists across Europe, is to coordinate and conduct multidisciplinary research efforts into Anaplastic Lymphoma Kinase (ALK)-driven cancers predominantly Anaplastic Large Cell Lymphoma (ALCL) and neuroblastoma – both being largely paediatric malignancies. Embedded into this established international research network, the ALKATRAS programme was developed to:

1- nurture and provide an excellent training environment to a cohort of 15 Early Stage Researchers (ESRs) to become confident, competent, independent and well-connected European scientists

2- facilitate research into ALK-related malignancies with the aim of informing more efficient, less toxic therapies

3- encourage networking across Europe of all parties with an interest in paediatric ALK-related cancers and to widen the net of our public outreach.

4- provide a focused platform for data presentation and discussion of latest advances, research findings related to ALK-induced cancers, specifically neuroblastoma and lymphoma

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

ESR of ALKATRAS at a training event in Brno, Czech Republic

Project information

ALKATRAS

Grant agreement ID: 675712

Project website

Status

Ongoing project

Start date

1 September 2015
End date

31 August 2019

Funded under:

H2020-EU.1.3.1.

Overall budget:

€ 3 849 199,56
EU contribution

€ 3 849 199,56

Coordinated by:

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Deliverables

Deliverables not available

Publications

Peer reviewed articles (18)

The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)

Author(s): Ivonne Montes-Mojarro, Julia Steinhilber, Irina Bonzheim, Leticia Quintanilla-Martinez, Falko Fend

Published in: Cancers, Issue 10/4, 2018, Page(s) 107, ISSN 2072-6694

DOI: 10.3390/cancers10040107

Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma

Author(s): Matteo Menotti, Chiara Ambrogio, Taek-Chin Cheong, Chiara Pighi, Ines Mota, Seth H. Cassel, Mara Compagno, Qi Wang, Riccardo Dall’Olio, Valerio G. Minero, Teresa Poggio, Geeta Geeta Sharma, Enrico Patrucco, Cristina Mastini, Ramesh Choudhari, Achille Pich, Alberto Zamo, Roberto Piva, Silvia Giliani, Luca Mologni, Clayton K. Collings, Cigall Kadoch, Carlo Gambacorti-Passerini, Luigi D. Notarangelo, Ines M. Anton, Claudia Voena, Roberto Chiarle

Published in: Nature Medicine, Issue 25/1, 2019, Page(s) 130-140, ISSN 1078-8956

DOI: 10.1038/s41591-018-0262-9

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells

Author(s): Luca Mologni, Mariantonia Costanza, Geeta Geeta Sharma, Michela Viltadi, Luca Massimino, Stefania Citterio, Stefania Purgante, Hima Raman, Alessandra Pirola, Massimo Zucchetti, Rocco Piazza, Carlo Gambacorti-Passerini

Published in: Neoplasia, Issue 20/5, 2018, Page(s) 467-477, ISSN 1476-5586

DOI: 10.1016/j.neo.2018.02.009

Targeting Autophagy in ALK-Associated Cancers

Author(s): Julie Frentzel, Domenico Sorrentino, Sylvie Giuriato

Published in: Cancers, Issue 9/12, 2017, Page(s) 161, ISSN 2072-6694

DOI: 10.3390/cancers9120161

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma

Author(s): Nikolai Schleussner, Olaf Merkel, Mariantonia Costanza, Huan-Chang Liang, Franziska Hummel, Chiara Romagnani, Pawel Durek, Ioannis Anagnostopoulos, Michael Hummel, Korinna Jöhrens, Antonia Niedobitek, Patrick R. Griffin, Roberto Piva, Henrike L. Sczakiel, Wilhelm Woessmann, Christine Damm-Welk, Christian Hinze, Dagmar Stoiber, Bernd Gillissen, Suzanne D. Turner, Eva Kaergel, Linda von Hoff, Michael Grau, Georg Lenz, Bernd Dörken, Claus Scheidereit, Lukas Kenner, Martin Janz, Stephan Mathas

Published in: Leukemia, Issue 32/9, 2018, Page(s) 1994-2007, ISSN 0887-6924

DOI: 10.1038/s41375-018-0045-9

Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Author(s): Alessandro Prestipino, Alica J. Emhardt, Konrad Aumann, David O’Sullivan, Sivahari P. Gorantla, Sandra Duquesne, Wolfgang Melchinger, Lukas Braun, Slavica Vuckovic, Melanie Boerries, Hauke Busch, Sebastian Halbach, Sandra Pennisi, Teresa Poggio, Petya Apostolova, Pia Veratti, Michael Hettich, Gabriele Niedermann, Mark Bartholomä, Khalid Shoumariyeh, Jonas S. Jutzi, Julius Wehrle, Christine Dierks, Heiko Becker, Annette Schmitt-Graeff, Marie Follo, Dietmar Pfeifer, Jan Rohr, Sebastian Fuchs, Stephan Ehl, Frederike A. Hartl, Susana Minguet, Cornelius Miething, Florian H. Heidel, Nicolaus Kröger, Ioanna Triviai, Tilman Brummer, Jürgen Finke, Anna L. Illert, Eliana Ruggiero, Chiara Bonini, Justus Duyster, Heike L. Pahl, Steven W. Lane, Geoffrey R. Hill, Bruce R. Blazar, Nikolas von Bubnoff, Erika L. Pearce, Robert Zeiser

Published in: Science Translational Medicine, Issue 10/429, 2018, Page(s) eaam7729, ISSN 1946-6234

DOI: 10.1126/scitranslmed.aam7729

The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas

Author(s): Ines Garces de los Fayos Alonso, Huan-Chang Liang, Suzanne Turner, Sabine Lagger, Olaf Merkel, Lukas Kenner

Published in: Cancers, Issue 10/4, 2018, Page(s) 93, ISSN 2072-6694

DOI: 10.3390/cancers10040093

Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling

Author(s): Melanie R. Hassler, Walter Pulverer, Ranjani Lakshminarasimhan, Elisa Redl, Julia Hacker, Gavin D. Garland, Olaf Merkel, Ana-Iris Schiefer, Ingrid Simonitsch-Klupp, Lukas Kenner, Daniel J. Weisenberger, Andreas Weinhaeusel, Suzanne D. Turner, Gerda Egger

Published in: Cell Reports, Issue 17/2, 2016, Page(s) 596-608, ISSN 2211-1247

DOI: 10.1016/j.celrep.2016.09.018

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma

Author(s): Serena Stadler, Vijay Singh, Fabian Knörr, Christine Damm-Welk, Wilhelm Woessmann

Published in: Cancers, Issue 10/4, 2018, Page(s) 114, ISSN 2072-6694

DOI: 10.3390/cancers10040114

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability

Author(s): Cosimo Lobello, Vasilis Bikos, Andrea Janikova, Sarka Pospisilova

Published in: Cancers, Issue 10/3, 2018, Page(s) 64, ISSN 2072-6694

DOI: 10.3390/cancers10030064

Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond

Author(s): Nina Prokoph, Hugo Larose, Megan Lim, G. Burke, Suzanne Turner

Published in: Cancers, Issue 10/4, 2018, Page(s) 99, ISSN 2072-6694

DOI: 10.3390/cancers10040099

ALK in Neuroblastoma: Biological and Therapeutic Implications

Author(s): Ricky Trigg, Suzanne Turner

Published in: Cancers, Issue 10/4, 2018, Page(s) 113, ISSN 2072-6694

DOI: 10.3390/cancers10040113

Comment on “ALK is a therapeutic target for lethal sepsis”

Author(s): Rafael B. Blasco, Enrico Patrucco, Ines Mota, Wei-Tien Tai, Roberto Chiarle

Published in: Science Translational Medicine, Issue 10/471, 2018, Page(s) eaar4321, ISSN 1946-6234

DOI: 10.1126/scitranslmed.aar4321

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia

Author(s): Barbara Maurer, Harini Nivarthi, Bettina Wingelhofer, Ha Thi Than Pham, Michaela Schlederer, Tobias Suske, Reinhard Grausenburger, Ana-Iris Schiefer, Michaela Prchal-Murphy, Doris Chen, Susanne Winkler, Olaf Merkel, Christoph Kornauth, Maximilian Hofbauer, Birgit Hochgatterer, Gregor Hoermann, Andrea Hoelbl-Kovacic, Jana Prochazkova, Cosimo Lobello, Abbarna A. Cumaraswamy, Johanna Latzka, Melitta Kitzwögerer, Andreas Chott, Andrea Janikova, Šárka Pospíšilova, Joanna I. Loizou, Stefan Kubicek, Peter Valent, Thomas Kolbe, Florian Grebien, Lukas Kenner, Patrick T. Gunning, Robert Kralovics, Marco Herling, Mathias Müller, Thomas Rülicke, Veronika Sexl, Richard Moriggl

Published in: Haematologica, 2019, Page(s) haematol.2019.216986, ISSN 0390-6078

DOI: 10.3324/haematol.2019.216986

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Author(s): Peng Liu, Liwei Zhao, Jonathan Pol, Sarah Levesque, Adriana Petrazzuolo, Christina Pfirschke, Camilla Engblom, Steffen Rickelt, Takahiro Yamazaki, Kristina Iribarren, Laura Senovilla, Lucillia Bezu, Erika Vacchelli, Valentina Sica, Andréa Melis, Tiffany Martin, Lin Xia, Heng Yang, Qingqing Li, Jinfeng Chen, Sylvère Durand, Fanny Aprahamian, Deborah Lefevre, Sophie Broutin, Angelo Paci, Amaury Bongers, Veronique Minard-Colin, Eric Tartour, Laurence Zitvogel, Lionel Apetoh, Yuting Ma, Mikael J. Pittet, Oliver Kepp, Guido Kroemer

Published in: Nature Communications, Issue 10/1, 2019, ISSN 2041-1723

DOI: 10.1038/s41467-019-09838-y

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma

Author(s): Nicole Prutsch, Elisabeth Gurnhofer, Tobias Suske, Huan Chang Liang, Michaela Schlederer, Simone Roos, Lawren C. Wu, Ingrid Simonitsch-Klupp, Andrea Alvarez-Hernandez, Christoph Kornauth, Dario A. Leone, Jasmin Svinka, Robert Eferl, Tanja Limberger, Astrid Aufinger, Nitesh Shirsath, Peter Wolf, Thomas Hielscher, Fritz Aberger, Johannes Schmoellerl, Dagmar Stoiber, Birgit Strobl, Ulrich Jäger, Philipp B. Staber, Florian Grebien, Richard Moriggl, Mathias Müller, Giorgio G. Inghirami, Takaomi Sanda, A. Thomas Look, Suzanne D. Turner, Lukas Kenner, Olaf Merkel

Published in: Leukemia, Issue 33/3, 2019, Page(s) 696-709, ISSN 0887-6924

DOI: 10.1038/s41375-018-0239-1

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

Author(s): Geeta Sharma, Ines Mota, Luca Mologni, Enrico Patrucco, Carlo Gambacorti-Passerini, Roberto Chiarle

Published in: Cancers, Issue 10/3, 2018, Page(s) 62, ISSN 2072-6694

DOI: 10.3390/cancers10030062

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Published in: Nature Communications, Issue 10/1, 2019, ISSN 2041-1723

DOI: 10.1038/s41467-019-09415-3

Project information

ALKATRAS

Grant agreement ID: 675712

Project website

Status

Ongoing project

Start date

1 September 2015
End date

31 August 2019

Funded under:

H2020-EU.1.3.1.

Overall budget:

€ 3 849 199,56
EU contribution

€ 3 849 199,56

Coordinated by:

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Project information

ALKATRAS

Grant agreement ID: 675712

Project website

Status

Ongoing project

Start date

1 September 2015
End date

31 August 2019

Funded under:

H2020-EU.1.3.1.

Overall budget:

€ 3 849 199,56
EU contribution

€ 3 849 199,56

Coordinated by:

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Download

PDF

XML

Last update: 2 April 2019

Record number: 198302

CORDIS

Objective

Coordinator

Participants (12)

Partners (10)

Project information

Periodic Reporting for period 1 - ALKATRAS (ALK Activation as a target of TRAanslational Science (ALKATRAS): Break free from cancer)

Project information

Deliverables

Publications

Project information

Project information

Share this page

Download